@article{d5f311134b414294a980163cdf4a38b7,
title = "Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques",
abstract = "Prevention of mother-to-child transmission (MTCT) of HIV remains a major objective where antenatal care is not readily accessible. We tested HIV-1-specific human neutralizing monoclonal antibodies (NmAbs) as a post-exposure therapy in an infant macaque model for intrapartum MTCT. One-month-old rhesus macaques were inoculated orally with the simian-human immunodeficiency virus SHIV SF162P3. On days 1, 4, 7 and 10 after virus exposure, we injected animals subcutaneously with NmAbs and quantified systemic distribution of NmAbs in multiple tissues within 24 h after antibody administration. Replicating virus was found in multiple tissues by day 1 in animals that were not treated. All NmAb-treated macaques were free of virus in blood and tissues at 6 months after exposure. We detected no anti-SHIV T cell responses in blood or tissues at necropsy, and no virus emerged after CD8 + T cell depletion. These results suggest that early passive immunotherapy can eliminate early viral foci and thereby prevent the establishment of viral reservoirs.",
author = "Hessell, {Ann J.} and Jaworski, {J. Pablo} and Erin Epson and Kenta Matsuda and Shilpi Pandey and Christoph Kahl and Jason Reed and Sutton, {William F.} and Katherine Hammond and Cheever, {Tracy A.} and Barnette, {Philip T.} and Legasse, {Alfred W.} and Shannon Planer and Stanton, {Jeffrey J.} and Amarendra Pegu and Xuejun Chen and Keyun Wang and Don Siess and David Burke and Park, {Byung S.} and Axthelm, {Michael K.} and Anne Lewis and Hirsch, {Vanessa M.} and Graham, {Barney S.} and Mascola, {John R.} and Sacha, {Jonah B.} and Haigwood, {Nancy L.}",
note = "Funding Information: We thank D. Malherbe for helpful discussions and C. Corbacci for graphic design work. We appreciate the expertise, dedication and thoughtful care provided to the infant macaques by H. Sidener and the ONPRC nursery animal care technicians. Titrated stocks of SHIVSF162P3 (passage 3) virus were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases NIAID), NIH (catalog number 6526; contributors J. Harouse, C. Cheng-Mayer and R. Pal) for each study. The SIVsmE660 stock was kindly provided by V.M. Hirsch. The linearized pBSII-SIVgag was kindly gifted by Michael Piatak, National Cancer Institute at the NIH. Funding was provided by US Public Health Service grants from the NIH (grant no. R01-HD080459 (N.L.H.), P51-OD011092 (J. Robertson), P51-OD011092 pilot funding (E.E.)), the Elizabeth Glaser Pediatric AIDS Foundation (N.L.H.) and the American Foundation for AIDS Research (amfAR) (grant no. 108823-55-RGRL; N.L.H.). This work was also funded, in part, by the intramural research program of the Vaccine Research Center (B.S.G. and J.R.M.) and the Laboratory of Molecular Microbiology, NIAID, NIH, Division of Health and Human Services, US Public Health Service (V.M.H.). Publisher Copyright: {\textcopyright} 2016 Nature America, Inc. All rights reserved.",
year = "2016",
month = apr,
day = "1",
doi = "10.1038/nm.4063",
language = "English (US)",
volume = "22",
pages = "362--368",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",
}